Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Kelley Gipson

Guilford, Branford biotechs fight COVID-19

Federal regulators have green-lighted Guilford’s AI Therapeutics to begin a clinical trial to test if its experimental drug for non-Hodgkin lymphoma and ALS could also...

| By Kelley Gipson

BioCT welcomes new member AlloMek

AlloMek Therapeutics is a privately held company focused on developing macrocycles for treating rare diseases. AlloMek’s most advance candidate, CIP-137401, is an IND ready molecule...

| By Kelley Gipson

UConn studying obesity, pediatric hydrocephalus

Two University of Connecticut Health researchers will investigate the regulators of a cell type that plays a critical role in metabolic diseases associated with obesity....

| By Kelley Gipson

Azitra garners pediatric disease designation

Azitra reports that the FDA has granted Rare Pediatric Disease Designation to ATR-12 for the treatment of Netherton syndrome, a chronic genetic skin disease that can...

| By Kelley Gipson

BMS CEO optimistic re future of medical research

Giovanni Caforio, chairman and CEO of Bristol Myers Squibb, was recently interviewed in Fortune: “If there is any good news coming out of the coronavirus pandemic, it’s...

| By Kelley Gipson

Biohaven and Arvinas add to Board of Directors

Biohaven reports the appointment of pharmaceutical industry leader Robert J. Hugin to its board of directors, effective immediately. Hugin previously was chairman and chief executive officer...

| By Kelley Gipson

P2 Science closes $3 million line of credit

P2 Science has closed on a $3 million line of credit with Webster Bank. The company, which has a manufacturing plant in Naugatuck and research...

| By Kelley Gipson

BIO Digital sessions now available on demand

Last week at BIO Digital, Dr. Michelle McMurry-Heath, BIO’s President & CEO, moderated the panel “Leading Through Crisis: Speaking Up and Out on Equity, Diversity,...

| By Kelley Gipson

Azitra moves to Branford to accommodate growth

Azitra has opened its new 12,000 square foot laboratory and office complex in Branford, CT. Previously operating out of three small labs located at the...

| By Kelley Gipson

CT medical marijuana program to treat chronic pain

The Connecticut Legislature’s Regulations Review Committee has approved two new conditions to allow patients with chronic pain and an inherited disorder that affects the body’s...